Discovery of potential anti-SARS-CoV-2 drugs based on large-scale screening in vitro and effect evaluation in vivo

AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells

(2021) Shuai Wang et al.   CELL RESEARCH

From Hydroxychloroquine to Ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?

(2021) S Rakedzon et al.   JOURNAL OF TRAVEL MEDICINE

Evaluation of the efficacy and safety of hydroxychloroquine in comparison with chloroquine in moderate and severe patients with COVID-19

(2021) Qiuyu Li et al.   Science China-Life Sciences

A novel cell culture system modeling the SARS-CoV-2 life cycle

(2021) Xiaohui Ju et al.   PLoS Pathogens

Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs against Ebola Virus In Vivo

(2021) Courtney L. Finch et al.   Microorganisms

Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: In Vitro Activity against SARS-CoV-2 and Potential Mechanisms

(2021) Ana C. Puhl et al.   ACS Omega

Erratum for Herring et al., “Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs”

(2021) Shawn Herring et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

β-D-N 4-hydroxycytidine (NHC) Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells

(2021) Shuntai Zhou et al.   JOURNAL OF INFECTIOUS DISEASES

The Repurposed Drugs Suramin and Quinacrine Cooperatively Inhibit SARS-CoV-2 3CLpro In Vitro

(2021) Raphael J. Eberle et al.   Viruses-Basel

Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2

(2021) Mark Dittmar et al.   Cell Reports

Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods

(2021) Tiziana Ginex et al.   Pharmaceuticals

Published anti-SARS-CoV-2 in vitro hits share common mechanisms of action that synergize with antivirals

(2021) Jing Xing et al.   BRIEFINGS IN BIOINFORMATICS

Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19

(2021) Carmen Mirabelli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2

(2021) Nir Drayman et al.   SCIENCE

A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entry

(2021) Yanwen Chen et al.   Nature Communications

Viral fibrotic scoring and drug screen based on MAPK activity uncovers EGFR as a key regulator of COVID-19 fibrosis

(2021) Elmira R. Vagapova et al.   Scientific Reports

SARS-CoV-2 infection in the Syrian hamster model causes inflammation as well as type I interferon dysregulation in both respiratory and non-respiratory tissues including the heart and kidney

(2021) Magen Ellen Francis et al.   PLoS Pathogens

Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports

(2021) Elisabeth Mahase   BMJ-British Medical Journal

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

(2020) Manli Wang et al.   CELL RESEARCH

Identification of patients with smouldering multiple myeloma at ultra‐high risk of progression using serum parameters: the Czech Myeloma Group model

(2020) Roman Hájek et al.   BRITISH JOURNAL OF HAEMATOLOGY

The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target

(2020) Mohamed Abu-Farha et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

(2020) Joshua Geleris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Repurposing old drugs as antiviral agents for coronaviruses

(2020) Cheng-Wei Yang et al.   Biomedical Journal

The Global Phosphorylation Landscape of SARS-CoV-2 Infection

(2020) Mehdi Bouhaddou et al.   CELL

The assessment of transmission efficiency and latent infection period on asymptomatic carriers of SARS-CoV-2 infection

(2020) Zhirong Liu et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications

(2020) Konstantinos Farsalinos et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Repositioning of 8565 Existing Drugs for COVID-19

(2020) Kaifu Gao et al.   Journal of Physical Chemistry Letters

Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing

(2020) Laura Riva et al.   NATURE

A study on infectivity of asymptomatic SARS-CoV-2 carriers

(2020) Ming Gao et al.   RESPIRATORY MEDICINE

Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs

(2020) Bo Yu et al.   Science China-Life Sciences

Potential Antiviral Options against SARS-CoV-2 Infection

(2020) Aleksandr Ianevski et al.   Viruses-Basel

Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements

(2020) Abhjieet Pandey et al.   LIFE SCIENCES

Spike mutation D614G alters SARS-CoV-2 fitness

(2020) Jessica A. Plante et al.   NATURE

A comprehensive drug repurposing study for COVID19 treatment: novel putative dihydroorotate dehydrogenase inhibitors show association to serotonin–dopamine receptors

(2020) Burak Berber et al.   BRIEFINGS IN BIOINFORMATICS

Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity

(2020) Erik Volz et al.   CELL

Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2

(2020) Xia Xiao et al.   Frontiers in Immunology

Metascape provides a biologist-oriented resource for the analysis of systems-level datasets

(2019) Yingyao Zhou et al.   Nature Communications

Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia

(2017) Masamichi Mori et al.   INVESTIGATIONAL NEW DRUGS

Antiviral activity of lanatoside C against dengue virus infection

(2014) Yan Yi Cheung et al.   ANTIVIRAL RESEARCH

The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry

(2014) Gerrit Gehring et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Reduction of influenza virus-induced lung inflammation and mortality in animals treated with a phosophodisestrase-4 inhibitor and a selective serotonin reuptake inhibitor

(2013) Geeta Sharma et al.   Emerging Microbes & Infections

Three Different Functional Microdomains in the Hepatitis C Virus Hypervariable Region 1 (HVR1) Mediate Entry and Immune Evasion

(2012) Mo Guan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Salinomycin as a Drug for Targeting Human Cancer Stem Cells

(2012) Cord Naujokat et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY